Introduction
The mechanism of T cell-mediated autoimmunity has been widely investigated in transgenic mice which expressed self antigens (Ags) under the control of tissue-specific promoters. Given the prominent role played by T cells in pathogenicity of diabetes mellitus type I, efforts were made particularly to unravel the nature of T cell tolerance to pancreatic islet  cell Ags. In some of these studies, viral proteins were expressed in pancreatic islets (1, 2) . Autoimmune diabetes did not occur in these mice, unless they were infected with the respective virus. These seminal studies demonstrated that CD8 + T cells with specificity for model self antigens usually ignore their specific self antigens under normal circumstances, but could be induced to become auto-aggressive by cross-reactive pathogen-associated Ags (3) .
It is now generally been recognized that CD4 + helper T (Th) cells are essential for induction of CD8 + cytotoxic T lymphocyte (CTL) responses against many cell-based Ags, including male-specific Ags, model Ags loaded onto splenocytes, or tumor Ags transfected into cell lines (4) (5) (6) . Further, it was shown that many cell-based Ags activate CD8 + CTLs through the cross-priming pathway, which involves bone marrow-derived Ag-presenting cells (APCs) that take up exogenous Ags and present them via the major histocompatibility complex (MHC) class I pathway (7, 8) . Thus, CD4 + T cells are also essential for in vivo crosspriming (4-6) and avoiding induction of CTL tolerance (9) . Several studies have implicated CD40 signaling (6, 10) control of rat insulin promoter (RIP), Behrens and colleagues attempted to define the nature of CD4 + T cell help for induction of islet  cell destruction and diabetes by CTL effectors (10) . They demonstrated that the effector phase of CTL responses is influenced by CD4 + T cell help and that CD154 signaling is an important helper factor provided by CD4 + T cells in induction of CD8 + CTL responses. Although considerable knowledge has been acquired in T cell activation, the factors that contributed by the CD4 + T cell help in CD8 + CTL generation are still not well understood (11, 12) .
Stimulation of T cells by APCs involves at least two signaling events: one elicited by T cell receptor (TCR) recognition of peptide-MHC (pMHC) complexes and the other by costimulatory molecule signaling (e.g., T cell CD28/ APC CD80) (11, 13) . Consequent to Ag-specific T cell-APC interactions, immunological synapse is formed comprising a central cluster of TCR-MHC-peptide complexes and CD28-CD80 interactions surrounded by rings of engaged accessory molecules (e.g., complexed LFA-1-CD54) (14, 15) . It has been demonstrated that APC-derived surface molecules are transferred to the Th cells during the course of their TCR internalization (16). Recently, we have shown that CD4 + T cells can acquire not only the synapse-composed MHC class II and costimulatory molecules (CD54 and CD80), but also the bystander pMHC I from APCs, and act as CD4 + Th-APCs in stimulation of CTL responses (11) . Although, the efforts to delineate the role played by MHC class II in induction of CTL responses have been investigated in RIP-OVA hi mice (10, 17) , the contribution of pMHC I acquisition by CD4 + Th cells in CTL responses resulting in pancreatic islet  cell destruction and diabetes is elusive.
In this study, we chose a well studied transgenic mouse model, RIP-mOVA mice with moderate expression of self OVA Ag and OVA-specific self immune tolerance (17) to retest the stimulatory effect of CD4 + Th cells with or without acquired pMHC I complexes. We then investigated the role of acquired pMHC I complexes on DC OVA -activated CD4 + Th cells in activation of OVA-specific CD8 + CTL responses in wild-type C57BL/6 mice and transgenic RIP-mOVA mice with self OVA-specific tolerance. Our results clearly demonstrated a targeting role of acquired pMHC I complexes on CD4 + Th cells in stimulation of OVA-specific CD8 + CTL responses leading to destruction of islet  cells and diabetes in transgenic RIP-mOVA mice. This study thus expands the current knowledge in T cell-mediated autoimmunity and provides insight into the nature of CD4 + T cell-mediated help in CD8 + CTL induction. MN) . Female C57BL/6 mice (B6) were obtained from Charles River Laboratories (St. Laurent, Quebec, Canada). The OVA-specific TCR transgenic OT-I and OT-II mice (11) , and H-2K b gene knockout (KO) mice on C57BL/6 background were purchased from the Jackson Laboratory (Bar Harbor, MA). Homozygous OT-II/H-2K b-/-mice were generated by backcrossing the designated gene KO mice onto the OT-II background for three generations, homozygosity was confirmed by polymerase chain reaction (PCR) according to Jackson Laboratory's protocols. The transgenic rat insulin promoter (RIP)-mOVA mice on C57BL/6 background were obtained from Dr. W. Heath, Walter and Eliza Hall Institute of Medical Research (Melbourne, Australia) (17). These transgenic mice express OVA under the RIP and have, as such, OVA as a neo-self-Ag. They are transgenic for truncated OVA gene that is expressed as a membrane-bound molecule in pancreatic islets, kidney proximal tubules, and testis of male mice. All mice were treated according to animal care committee guidelines of University of Saskatchewan.
Materials and Methods

Reagents
Generation of bone marrow-derived dendritic cells
The preparation of bone marrow (BM)-derived dendritic cells (DCs) was previously described (11) . Briefly, BM cells prepared from femora and tibiae of normal C57BL/6 mice were depleted of red blood cells with 0.84% ammonium chloride and plated in DC culture medium [DMEM plus 10% FCS, GM-CSF (20 ng/ml) and IL-4 (20 ng/ml)]. On day 3, the nonadherent granulocytes, and T and B cells were gently removed, and fresh media were added. Two days later, the loosely-adherent proliferating DC aggregates were dislodged and replated. On day 6, the nonadherent cells were harvested. These DCs were pulsed with OVA (0.3 mg/ml) for overnight at 37°C, then washed extensively with PBS, and termed DC OVA . DCs generated from the H-2K b gene KO mice were referred to as (K b-/-) DC OVA .
Preparation of OT-II CD4
+ and OT-I CD8 + T cells Naïve OVA-specific CD4 + T and CD8 + T cells were isolated from OT-II and OT-I mouse spleens, respectively, and enriched by passage through nylon wool columns (C&A Scientific Inc, VA). CD4 + and CD8 + T cells were then purified by negative selection using anti-mouse CD8 (Ly2) and CD4 (L3T4) paramagnetic beads (DYNAL Inc, Lake Success, NY) to yield populations that were > 95% CD4 + + T cells were stained with Abs specific for CD4, CD69 and pMHC I, respectively, and analyzed by flow cytometry. To examine the intracellular expression of cytokines, the above cells were processed using a commercial kit (Cytofix/CytoPerm Plus with GolgiPlug; Pharmingen, Inc), and stained with PE-conjugated anti-IL-4 and IFN- Abs, according to the manufacturers' protocols (11) . Cytokine secretion of CD4 + Th cells in the supernatants was assessed using the commercial enzyme-linked immunosorbent assay (ELISA) kits (Endogen, Woburn, MA). The results were normalized to the recombinant cytokine standard curves.
T cell proliferation assay C57BL/6 mice and RIP-mOVA mice were i.v. immunized with DC OVA (1 × 10 6 cells per mouse) and CD4 + Th or (K b-/-) Th cells (3 × 10 6 cells per mouse), respectively. Six days after the immunization, 100 l blood was taken from the tail of each mouse. The blood samples were incubated with 10 l PE-conjugated H-2K b /OVA 257-264 tetramer (Beckman coulter, Mississauga, Ontario, Canada) and 1 l FITC-conjugated anti-CD8 mAb for 30 min at room temperature. The erythrocytes were then lysed using lysis/fixed buffer (Beckman coulter). The cells were washed and analyzed by flow cytometry.
Cytotoxicity assay C57BL/6 mice and RIP-mOVA mice were i.v. immunized with DC OVA, CD4 + Th or CD4 + (K b-/-) T cells (3 × 10 6 cells per mouse), respectively. Naïve mouse splenocytes were incubated with either high (3.0 M, CFSE high ) or low (0.6 M, CFSE low ) concentrations of CFSE, to generate differentially labeled target cells. The CFSE high cells were pulsed with OVA I, whereas the CFSE low cells were pulsed with the irrelevant 3LL lung carcinoma H-2K b peptide Mut1 and served as internal controls. These peptide-pulsed target cells were washed extensively to remove free peptide, and then i.v. co-injected at 1:1 ratio into the above immunized mice six days after the immunization. Sixteen hours after target cell delivery, the spleens were removed and residual CFSE high and CFSE low target cells remaining in the recipients' spleens were sorted and analyzed by flow cytometry.
Animal studies
In RIP-mOVA mice model, the cross-presentation of self OVA Ag was able to delete the autoreactive CD8 + T cells leading to tolerization of the CD8 + T cell compartment to self-Ag OVA (9) . We have recently demonstrated that (i) a high frequency of OVA-specific CD8 + T cell precursor can overcome OVA-specific immune tolerance from DC OVA immunization in RIP-mOVA mice and ( 
Results
Activated CD4
+ Th cells acquire pMHC I complexes from DC OVA by DC OVA activation We showed that OVA-pulsed dendritic cells (DC OVA ) expressed H-2K b , Ia b , CD11c, CD80 and pMHC I ( Figure  1A ), indicating that they are OVA-specific mature DCs. We previously showed that in vitro DC OVA -activated OT-II CD4 + T cells acquired DC's MHC I and II and costimulatory molecules (CD54 and CD80) (11) . In this study, we more accurately assessed the acquisition of DC's pMHC I complexes by CD4 + Th cells using the specific anti-pMHC I Ab. As shown in Figure 1B, Figure 1C ), confirming that these activated CD4 + T cells do acquire pMHC I from DC OVA by DC OVA activation. To rule out the possibility of irradiated-DC OVA contamination in these activated CD4
+ Th cell population, we also analyzed them using the anti-CD4 and anti-CD11c Abs specific for CD4 + T cell and DC markers, respectively, by flow cytometry. There was no detectable CD11c + DC OVA contamination in purified activated CD4
+ Th cell population (data not shown) due to not only the powerful positive selection process, but also the killing activity of these activated CD4 + Th cells expressing OVA-specific TCR to pMHC II-expressing DC OVA (21). performed tetramer staining assay to detect OVA-specific CD8 + T cells in these immunized mice. As shown in Figure  2A Figure 2B ), RIPmOVA mice did not respond to the above stimulation with OVA-specific T cell responses which accounted for only 0.06% of the total peripheral blood CD8 + T cells ( Figure 3A ). However, they also resumed their responses to DC OVA stimulation after the treatment of mice with anti-CD25 Ab to 
Activated
Tolerogenic dosage of activated CD4 + Th cells has stimulatory effect on CD8 + T cells only in presence of OT-I CD8 + T cell precursors in RIP-mOVA mice leading to islet tissue destruction and diabetes
To break the immune tolerance, RIP-mOVA mice with a previous transfer of 1 × 10 6 OT-I CD8 + T cells were immunized with different amounts of CD4 + Th cells, and then monitored for 2 weeks for diabetes by urine glucose testing. We found that a previous transfer of a constant amount of OT-I T cells (1 × 10 6 cells) and subsequent injection of 0.1 × 10 6 , 0.5 × 10 6 , 1 × 10 6 and 2 × 10 6 activated CD4 + T cells with acquired pMHC I was able to induce diabetes in 0/10, 3/10, 6/10 and 8/10 RIP-mOVA mice, respectively. Diabetes which occurred 8-14 days after T cell transfer into these RIP-mOVA mice were further confirmed by histopathological examination of pancreas as evidenced by the destruction of pancreatic islet tissues with lymphocyte infiltration ( Figure 4A ). Our data are consistent with a previous report by Kurts and colleagues demonstrating that when OT-I and OT-II T cells co-injected, OT-II CD4 + T cells stimulate OT-I CD8 + T cells to destroy pancreatic  cells leading to diabetes in RIP-mOVA mice (9) . Here, it is interesting to note that 2 × 10 6 activated CD4 + (K b-/-) Th cells without acquired pMHC I were unable to induce diabetes in RIP-mOVA mice with previous transfer of 1 × 10 6 OT-I CD8 + T cells ( Figure 4A ), confirming the importance of acquired pMHC I in induction of diabetes in RIP-mOVA mice. To explain the fact that activated CD4 + T cells with acquired pMHC I mediated an enhanced CD8 + CTL response, we and others proposed that activated CD4 + T cells could supply cytokines, such as IL-2 that may enhance the expansion and/or survival of CD8 + T cells (11, 22 ) and augment the survival of activated CD8 + T cells possibly due to the induction of survival genes like bcl-xL or other antiapoptotic mechanism (9, 23) thereby shifting the autoreactive CD8 + T cell response from tolerogenic to immunogenic pathway in RIP-mOVA mice. + T cells compared to either T-cell subset alone. Moreover, in a tissue transplantation study, graft rejection was pronounced by simultaneously raising the frequency of CD4 + T cells to 0.5% and CD8 + T cells to 5% despite CD28/CD154 blockade. Although the exact mechanism of specific protection of CTL responses by CD4 + Th cells is still unknown, Kennedy and Celis (23) 
Discussion
25
+ Tr cells (42). However, they did not elucidated the molecular mechanism on how the immune suppressive effect of these Tr cells can be specifically or more efficiently delivered to the in vivo T-cell-mediated graft rejections or autoimmune diseases. Based upon the above principle elucidated in this study, we assume that these CD4 + or DN Tr cells may become Ag-specific after acquisition of pMHC I or pMHC II complexes by DC stimulation in vivo. This assumption has recently been proved. It has been shown that these DN Tr cell-mediated antigen-specific suppression is via in vivo trogocytosis of alloantigen (43). We have also demonstrated that antigen specificity of adoptive CD4 + regulatory T cells was obtained via acquired pMHC I complexes from IL-10-secreting antigen-specific DCs by DC stimulation (44).
Taken together, our data provide direct evidence that it is the acquired pMHC I complexes on CD4 + Th cells that enhances CD4 + T cell helper effect in induction of CD8 + T cell-mediated pancreatic islet destruction and diabetes. Thus, the present findings may have significant implications in autoimmunity and antitumor immunotherapy. 
